VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.
Higher-risk Myelodysplastic Syndromes
DRUG: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT
Overall Survival, OS was defined as time from diagnosis to death from any cause or the last follow-up, 3 year
Progression Free Survival (PFS), For patients in morphologic remission, documented relapse was considered progression., 3 year|Incidence of acute GVHD and chronic GVHD, Incidence rate of acute GVHD and chronic GVHD, 3 year|Non-relapse mortality (NRM), Non-relapse mortality (NRM) was defined as death from any cause not subsequent to relapse., 3 year|Graft-versus-host disease (GVHD)-free relapse-free survival(GRFS), Graft-versus-host disease (GVHD)-free relapse-free survival(GRFS) was defined as petients without GVHD and relapse, 3 year
The investigators will evaluate 2 year overall survival(OS) after transplantation in patients with higher-risk MDS. Progression free survival (PFS), incidence of acute GVHD, non-relapse mortality (NRM), graft-versus-host disease (GVHD)-free relapse-free survival(GRFS), and incidence of chronic GVHD at 1 and 2 years after transplantation will be counted.